Catalyst Pharmaceuticals (CPRX +13.7%) perks up on almost a 5x surge in volume in response to its announcement of positive top-line results from an investigator-sponsored study in Italy assessing Firdapse (amifampridine phosphate) for the treatment of patients with myasthenia gravis (MG) with anti-MuSK antibodies, an ultra-rare subpopulation of MG patients. The company says both co-primary…
Myasthenia Gravis Trial Shows Encouraging Results
Myasthenia Gravis Trial Shows Encouraging Results Some positive news for Myasthenia Gravis (MG) patients. Catalyst Pharmaceuticals has reported that their clinical trial testing Firdapse (amifampridine phosphate) in MG patients with anti-MuSK antibodies (MuSK-MG) met its primary endpoint. About the trial The trial was a randomized, double blind, placebo-controlled, single site, outpatient study assessing Firdapse in…
Treatments for Myasthenia Gravis
Myasthenia gravis causes muscle weakness due to the immune system attacking neurotransmitter receptors on muscle tissue. Since the muscle can’t receive the signal to contract, people with myasthenia become weak. While this neuromuscular junction disorder used to always be disabling and even fatal, now it can usually be managed with various therapies. There are five general ways…
Myasthenia Gravis and Diet: Better Health and Weightloss
Living with Myasthenia Gravis can be challenging at a times. The way I learned to nourish my body for better health while living with Myasthenia Gravis should not be categorized as a diet at all but an eating style; one which has helped get me back on track with my health. Along with other critical factors such…